Pinnacle Financial Partners Inc. boosted its position in Bristol-Myers Squibb Company (NYSE:BMY) by 0.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,514 shares of the biopharmaceutical company’s stock after buying an additional 49 shares during the period. Pinnacle Financial Partners Inc.’s holdings in Bristol-Myers Squibb were worth $1,224,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the company. Intellectus Partners LLC purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth about $227,000. Franklin Resources Inc. increased its stake in shares of Bristol-Myers Squibb by 21.8% in the fourth quarter. Franklin Resources Inc. now owns 1,890,564 shares of the biopharmaceutical company’s stock worth $110,495,000 after buying an additional 338,461 shares during the last quarter. Roundview Capital LLC increased its stake in Bristol-Myers Squibb by 0.8% in the fourth quarter. Roundview Capital LLC now owns 12,420 shares of the biopharmaceutical company’s stock worth $726,000 after buying an additional 100 shares during the last quarter. Gratus Capital LLC increased its stake in Bristol-Myers Squibb by 0.5% in the fourth quarter. Gratus Capital LLC now owns 19,093 shares of the biopharmaceutical company’s stock worth $1,116,000 after buying an additional 104 shares during the last quarter. Finally, Barrington Strategic Wealth Management Group LLC increased its stake in Bristol-Myers Squibb by 0.4% in the fourth quarter. Barrington Strategic Wealth Management Group LLC now owns 16,855 shares of the biopharmaceutical company’s stock worth $985,000 after buying an additional 60 shares during the last quarter. Hedge funds and other institutional investors own 69.79% of the company’s stock.
Bristol-Myers Squibb Company (NYSE:BMY) traded up 0.63% during trading on Monday, reaching $56.30. 5,126,033 shares of the company’s stock were exchanged. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $64.77. The stock has a market cap of $92.33 billion, a PE ratio of 20.56 and a beta of 1.17. The firm has a 50 day moving average of $55.55 and a 200-day moving average of $54.50.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.69 EPS. On average, equities research analysts anticipate that Bristol-Myers Squibb Company will post $2.97 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, August 1st. Stockholders of record on Friday, July 7th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 2.77%. The ex-dividend date of this dividend was Wednesday, July 5th. Bristol-Myers Squibb’s payout ratio is 56.73%.
A number of equities research analysts have recently weighed in on the stock. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Deutsche Bank AG set a $55.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, July 17th. BMO Capital Markets downgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a research note on Wednesday, May 3rd. Jefferies Group LLC restated a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, July 12th. Finally, Piper Jaffray Companies set a $60.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Thursday, July 27th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $63.33.
In related news, Director Theodore R. Samuels II purchased 6,000 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, August 2nd. The stock was purchased at an average cost of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now owns 18,000 shares in the company, valued at approximately $1,006,920. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.
